Sequella Partnerships

• Daiichisankyo Co., Ltd. of Tokyo, is one of Japan's largest pharmaceutical companies, and has a long history of discovering new classes of drugs, including the statin class of lipid-lowering drugs. Sequella entered into an exclusive license agreement for Sankyo's novel anti-tuberculosis translocase inhibitors. These inhibitors represent a potential new class of anti-tuberculosis agents that act through specific inhibition of mycobacterial translocase I, an enzyme required for cell wall synthesis. Under the agreement, Sankyo granted Sequella an exclusive world-wide license to make, market and sell these compounds for all indications.
• Japan BCG Laboratory, Ltd, Tokyo, Japan, manufactures and sells Bacille Calmette-Guerin (BCG) vaccine and Purified Protein Derivative (PPD) skin test antigen for TB disease in Japan and limited markets outside Japan. Sequella licensed the TB Patch Test for active TB from the Japan BCG Laboratory. Under this agreement Sequella has worldwide rights to market and sell the Patch in all territories except Japan.
• Chembio Diagnostics, Inc. (CDI) develops and manufactures rapid tests to aid in the detection of infectious diseases including HIV and TB. Sequella and Chembio Diagnostics entered into a licensing agreement in which Sequella grants CDI, a wholly owned subsidiary of Chembio Systems, the exclusive rights to develop, manufacture, and market a rapid diagnostic test for the detection of TB in non-human primates (NHP).
• National Institutes of Health (NIH) is the focal point of biomedical research in the United States, and conducts research in its own laboratories; supports the research of non-Federal scientists in universities, medical schools, hospitals, and research institutions throughout the country and abroad; helps in the training of research investigators; and fosters communication of medical information. Since 2001, the NIH has supported Sequella in a variety of collaboration structures, including study grants to fund development of diagnostic products, scientific support for R&D of diamine TB compounds, analytical characterization of drug candidates, and in vivo toxicity and pharmacology testing of lead therapeutic compounds. In 2006, Sequella obtained an exclusive worldwide license from the NIH to develop SQ109, an IND-stage new chemical entity targeted for the treatment of tuberculosis (TB).
• Partners in Health (PIH) is a Massachusetts public health organization at Harvard University that is focused on setting up pilot programs to battle global diseases that affect the public health. PIH has provided funding to Sequella for a pilot study in Peru to assess the Bronx Box as a clinical diagnostic tool.